Le Lézard
Classified in: Health, Science and technology
Subjects: NPT, PDT

Novo Nordisk Foundation announces an international open call for research projects to address key global challenges


COPENHAGEN, Denmark, May 7, 2024 /PRNewswire/ -- As part of its Global Science Summit, the Novo Nordisk Foundation issues an international open call for research projects to catalyse science-based solutions to key global challenges. The programme expects to hand out up to eight grants with a total awarding budget of up to DKK 50 million (USD 7.1 million).

The Novo Nordisk Foundation is currently hosting its Global Science Summit in Helsingør, Denmark, as part of the celebrations for its 100th anniversary.

The Summit focuses on the interplay between non-communicable diseases, infectious diseases, and climate change as well as novel breakthrough-enabling technologies. The Summit brings together leading scientists, philanthropists and policymakers, with the overarching purpose of paving the way for new scientific breakthroughs that address these pressing issues.

In conjunction with the Summit, the Novo Nordisk Foundation is issuing an international open call for research projects, with the goal of catalysing science- and technology-based solutions to these global challenges. The expectation is to award up to eight grants, each with a budget of up to USD 1 million.

Professor Lene Oddershede, Senior Vice President at the Novo Nordisk Foundation, said: "As we celebrate our 100th anniversary, the Novo Nordisk Foundation is more committed than ever to helping to fund the scientific research needed to address the major globally complex and interconnected challenges humanity faces. We hope that these grants will achieve a lasting impact, and we encourage scientific communities all over the world to apply."

Organisations participating in the Global Science Summit as well as other relevant non-profit organisations will be invited to assemble project collaborations, each consisting of 2-3 partners, with the aim to explore a novel, focused and interdisciplinary idea that relates to the themes of the Summit. Each proposal should address at least two of the following thematic areas: climate change, non-communicable diseases, infectious diseases, and related enabling technologies. Applicants don't need to have attended the Global Science Summit to apply.

Further information is available on the Novo Nordisk Foundation's website.

About the Novo Nordisk Foundation

Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people's health and the sustainability of society and the planet. The Foundation's mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.

www.novonordiskfonden.dk/en 

SOURCE Novo Nordisk Foundation


These press releases may also interest you

at 17:55
City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

at 17:25
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
JDRF-Authored Paper Shows Pathway to Accelerate Disease-Modifying Therapies for People with Type 1 Diabetes
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

at 16:20
TOP-RANKED HEALTHCARE CONSULTING FIRM EXPANDS ROSTER, DEEPENS LEADERSHIP
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...

at 16:10
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...

More news about Health...


News published on and distributed by: